BABIO Introduces Influenza A/B Antigen Rapid Detection Kit

BABIO Introduces Influenza A/B Antigen Rapid Detection Kit

Seasonal Influenza A and B viruses remain a major public health threat worldwide, causing millions of respiratory infections each year. To support fast and reliable influenza diagnostics, BABIO, a leading Chinese manufacturer of in vitro diagnostic solutions, now offers the Influenza A/B Antigen Detection Kit (Colloidal Gold Method).

Rapid Dual Detection of Influenza A and B

This lateral flow immunoassay enables the qualitative detection of Influenza A and B antigens in patient samples. The kit features:

• Dual Test Lines (T1 & T2) – Separate detection of Influenza A and Influenza B antigens.

• Clear Results in 15 Minutes – Easy-to-read colored lines for fast decision-making.

• Built-In Control Line (C Line) – Ensures test validity with every run.

• Simple Workflow – Uses extraction buffer and dropper-based application, no lab equipment required.

Global Relevance in Outbreak Control

With influenza outbreaks reported in Europe, North America, Africa, and Southeast Asia, rapid antigen detection plays a critical role in clinical diagnosis, infection control, and outbreak surveillance. BABIO’s Influenza A/B Antigen Detection Kit offers healthcare providers a reliable, point-of-care tool to differentiate between Influenza A and B infections.

About BABIO

Founded in 2003, BABIO has grown into one of China’s well-recognized manufacturers of diagnostic reagents, rapid tests, and microbial detection kits. With ISO-certified facilities and international distribution, BABIO continues to provide innovative, cost-effective solutions for global healthcare needs.

👉 Learn more about the Influenza A/B Antigen Detection Kit at: https://www.babiocorp.com.

#Influenza #FluTest #RapidTestKit #InfectiousDisease #Diagnostics #BABIO #RespiratoryHealth #PointOfCare